Joshua Weisbrod, a partner with Bain & Company, said the industry was wrestling with uncertainty even prior to the election. Potential legislative and regulatory actions on drug pricing, the outcomes of payer consolidation efforts and the viability of, and possible changes to, public exchanges were among some of these issues facing health care prior to President Trump’s election.